Xencor Inc（XNCR）のニュースとイベントXNCRXencor Inc

Major Averages Rise as Investors Eye Earnings Week

The major averages were broadly higher near noon as investors prepare for an important week of earnings, the Federal Reserve's interest-rate decision and fresh inflation data. Markets are attempting to stabilize after the S&P 500 and Nasdaq Composite posted a second consecutive weekly decline, with investors weighing whether heavy artificial intelligence spending will translate into stronger earnings and cash flow.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Anthropic has publicly filed for an IPO on Nasdaq under the stock ticker "ANT"Metaannounced a $35B equity offering and plans for a $60B at-the-market program upon the commencement of trading of its recently announced Class C sharesSpaceXreported a $40B GPU equipment lease agreement with Apollo GlobalApolloannounced a strategic investment in Mubadala CapitalEQT Corporationagreed to acquire Range Resourcesin an all-stock transaction2. WALL STREET CALLS:Barclays upgraded Teslato Overweight, citing a merger opportunity with SpaceX, stronger core business outlook, and signs of Robotaxi inflectionBlockdowngraded to Equal Weight at Morgan StanleyNew Street upgraded Intelas CPU scarcity strengthens turnaroundAdvance Auto Partsdowngraded to Sell at Rothschild & Co Redburn and reinstated with an Underperform at BofAMorgan Stanley upgraded Lockheed Martinafter the company's F-35 production agreement3. AROUND THE WEB:Analysts expect companies in the S&P 500 to report profit growth of 30% in Q3 earnings compared to last year, yet Nvidiaand Micronare expected to account for 34% of that growth, WSJ saysAppletweaked macOS for its OLED touch MacBook Pro, due Wednesday, with a dynamic interface that adapts to whether touch or the trackpad was last used, Bloomberg reportsAnthropic'sClaude accessed Georgia voter data without human authorization, Axios saysNetflixusers are watching shows on the platform less and aren't opening the app on as many days a month as they did a few years prior, Bloomberg reportsVolkswagen'sAudi CEO Gernot Doellner defended his decision to stand alongside President Donald Trump during a rally in Perry, Georgia, Reuters says4. MOVERS:Surgery Partnersgains after Healthspan announced it will acquire the company for $23.50 per share in cashXtendincreases after reporting preliminary 9M revenue and appointing Matt McGraw as its U.S. CEOXencorhigher after announcing updated results from its Phase 1 study of XmAb819PagSeguroand Nu Holdingslower in New York after President Luiz Inacio Lula da Silva won Brazil's presidential runoffArcos Doradosfalls in New York after BofA downgraded the stock to Neutral5. EARNINGS/GUIDANCE:Verizonreported Q3 results and raised its outlook for FY26, with CEO Dan Schulman calling it "another record-breaking quarter"Easterly Government Propertiesreported Q3 results, raised its outlook for FY26, and provided its guidance for FY27Bank of Hawaiireported Q3 results, with EPS missing consensusHBT Financialreported Q3 results, with EPS and revenue beating consensusAlliance Resource Partnersreported Q3 results, with CEO Joseph Craft III noting it was "an outstanding third quarter"INDEXES:Near midday, the Dow was up 124.66, or 0.24%, to 52,339.82, the Nasdaq was up 273.69, or 1.05%, to 26,229.03, and the S&P 500 was up 61.37, or 0.80%, to 7,685.05.

Xencor Updates XmAb819 Study Results, Plans Registration by 2027

Xencor announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma, ccRCC. The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comprehensive Cancer Center, in a proffered paper oral presentation at the European Society for Medical Oncology, ESMO, Congress 2026 in Madrid, Spain. Xencor also reported additional follow-up data supporting selection of 400 mcg/kg as the intravenous proposed recommended Phase 3 dose and outlined plans for potential registration-enabling development by the end of 2027. Key highlights: 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate; Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC patient subgroups in 1H2027; Xencor plans global randomized study of monotherapy XmAb819 compared to tivozanib in a post PD-(L)1 and VEGFR TKI ccRCC patient population

Xencor to Initiate XmAb819 Registration Study in 2027

Xencor to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma. XmAb819 Evaluation Across Advanced ccRCC and ENPP3+ Tumors: XmAb819 is being evaluated for the treatment of patients with advanced ccRCC and ENPP3+ tumors in a Phase 1 clinical study. Xencor is planning to initiate a registration-enabling study of XmAb819 monotherapy in advanced ccRCC in 2027. Currently: Expansion cohorts are evaluating intravenous doses to support selection of a dose for the planned Phase 3 pivotal study for patients with advanced ccRCC, Dose escalation of subcutaneous administration in advanced ccRCC is ongoing, A sub-study for patients with ENPP3+ advanced colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma opened to enrollment in the second quarter of 2026, and A sub-study for patients with intermediate- or poor-risk advanced ccRCC who have progressed after nivolumab in combination with ipilimumab as a first-line treatment opened to enrollment in the third quarter of 2026.